e-learning
resources
Madrid 2019
Monday, 30.09.2019
Clinical approach to asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma
S. Swaminathan (New York, United States of America), A. Gerber (Denver, United States of America), K. Qirko (New York, United States of America), N. Wysham (Vancouver, United States of America), E. Corcoran (Portland, United States of America), T. Smith (Louisville, United States of America)
Source:
International Congress 2019 – Clinical approach to asthma management
Session:
Clinical approach to asthma management
Session type:
Thematic Poster
Number:
2724
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Swaminathan (New York, United States of America), A. Gerber (Denver, United States of America), K. Qirko (New York, United States of America), N. Wysham (Vancouver, United States of America), E. Corcoran (Portland, United States of America), T. Smith (Louisville, United States of America). A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma. 2724
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Identifying patients with severe asthma that will be benefit from biological therapy
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020
The use of omalizumab in the management of severe chronic paediatric asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019
Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019
Year: 2019
Combination asthma medication and healthcare use in severe or difficult-to-treat asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Year: 2019
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children
Source: Eur Respir J 2006; 28: Suppl. 50, 481s
Year: 2006
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations
Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Year: 2019
Pharmacological strategies for self-management of asthma exacerbations
Source: Eur Respir J 2006; 28: 182-199
Year: 2006
The prevalence of severe asthma in specialist care –identifying eligible candidates for biological therapies
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017
Use of relievers in patients with severe asthma on biologic therapy –a multidisciplinary approach
Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Year: 2020
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Two therapy option in patients with uncontrolled asthma
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Effects of an eHealth intervention promoting correct use of medication in patients with asthma and chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – Remote monitoring of respiratory patients
Year: 2021
Which patients with COPD can potentially benefit from prophylactic use of antibiotics?
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Feasibility and benefits of an innovative airway clearance device in COPD patients hospitalized for acute exacerbation
Source: Virtual Congress 2020 – New insights into determinants of patient-reported outcomes in chronic respiratory diseases
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept